Rio Biopharmaceuticals is lined up to copy 1 of the blockbuster drugs on this tracker, which earned $19.3B combined in 2025.
| Drug | Brand owner | Copy | US LOE | Rio Biopharmaceuticals' stage | 2025 brand sales |
|---|---|---|---|---|---|
| Ozempic | Novo Nordisk | Generic | 2032 | Filed with the FDA; settled, terms confidential | ≈$19.3B |
Each drug page lists sources for these entries. Brand sales show the size of the market, not Rio Biopharmaceuticals' share of it.
Rio Biopharmaceuticals has applications filed for Ozempic. It has settled with the brand owner over 1 drug. Of the 70 makers we follow, 38 are lined up to copy more of the drugs on this tracker.
Copies with no confirmed US launch, by the earliest year each could reach the market: a settlement date where one is public, otherwise the brand's US exclusivity date. "Now" means that date has passed. Court rulings and new patents can move these.